Case no | Type of disorder | Age | Gender | Comorbidity | COVID-19 test/history | Vaccine type | Time of incidence | Ref. |
---|---|---|---|---|---|---|---|---|
1 | Facial Paresis | 34 | Female | Migraine attacks (under treatment) | Not stated | Sputnik V | 1 day after the 1st dose | [31] |
2 | Encephalopathy | 27 | male | – | Not stated | ChAdOx1-S | 8 days after the 1st dose | [32] |
3 | 56 | Female | – | Negative | ChAdOx1-S | 2 days after the 1st dose | [20] | |
4 | Transverse myelitis | 31 | Female | – | Negative | ChAdOx1-S | 3 weeks after the 1st dose | [33] |
5 | Acute vestibular neuritis | 51 | Male | – | Negative | ChAdOx1-S | 11 days after the 1st dose | [34] |
6 | Bell's palsy | 27 | Female | – | Negative | Sputnik V | 3–5 days after the 1st dose | [35] |
7 | 58 | Male | Controlled diabetes mellitus | Not stated | Sputnik V | 10 days after the 1st dose | [35] | |
8 | Thalamic hemi-chorea | 72 | Male | History of laparoscopic cholecystectomy | Negative | ChAdOx1-S | 9 days after the 1st dose | [36] |
9 | Guillain–Barre syndrome | 60 | Male | Controlled hypertension and hypothyroidism | Negative | BBIBP–CorV | 20 days after the booster | [37] |
10 | 46 | Male | – | Negative | ChAdOx1-S | 3 days after the 2nd dose | [38] | |
11 | 36 | Male | – | Negative | BBIBP–CorV | 5 days after the 1st dose | [38] | |
12 | 32 | Male | – | Negative | BBIBP–CorV | 14 days after the 1st dose | [38] | |
13 | 68 | female | – | Negative | ChAdOx1-S | 4 days post the 2nd | [39] | |
14 | Aseptic meningitis | 26 | Female | – | Negative | ChAdOx1-S | A few hours the 1st dose | [40] |
15 | Extensive myelitis | 71 | Male | Diabetes mellitus, hypertension and Ischemic Heart Disease | Not stated | BBIBP–CorV | 5 days after the 1st dose | [41] |
16 | Acute disseminated encephalomyelitis | 37 | Male | – | Negative | BBIBP–CorV | few days to 1 month after the 1st dose | [42] |